Brief: Blueprint Medicines Q3 Net Income USD -56.276 Million Vs. IBES Estimate USD -60.9 Million
30/10/2024 11:01
Oct 30 (Reuters) - Blueprint Medicines Q3 product revenue USD 128.184 million. * Q3 operating expenses USD 177.158 million * Q3 pretax profit USD -56.003 million vs. IBES estimate USD -61 million * Q3 basic EPS USD -0.89
Recent news on Blueprint Medicines
See all newsBrief: Sanofi Announces Extension Of Blueprint Tender Offer
Brief: Blueprint Medicines Announces Data Reinforcing Safety Profile Of Long-Term Ayvakit
U.S. STOCKS ON THE MOVE-Texas Instruments, Broadcom, Circle
UBS raises Blueprint Medicines' PT on Sanofi's up to $9.5 billion takeover deal
U.S. RESEARCH ROUNDUP-Biomea Fusion, GE Aerospace, P&G